Skip to main content
Full access
APA & Meetings
Published Online: 4 February 2020

NIDA to Present Sessions on SUDs, Youth Development

The National Institute on Drug Abuse’s three sessions will focus on SUDs and psychiatric comorbidities, complex conditions of patients with OUD, and early brain development.
During APA’s 2020 Annual Meeting, the National Institute on Drug Abuse (NIDA) is sponsoring three sessions highlighting the latest research findings on substance use disorders (SUD) and how they might apply to both research and practice.
One session will discuss findings on the large, underserved population of patients with SUD and psychiatric comorbidities and explore strategies to accelerate the development of evidence-based, integrative treatments for this population. Clinical care of SUD has conventionally been separated from the treatment of other psychiatric conditions, and research has tended to examine either one or the other. Yet understanding how SUD and co-occurring mental health conditions present together in patients—and how they interact—can be essential for proper diagnosis and treatment of both.
The session, titled “Translational Perspectives on Psychiatric Comorbidities in Substance Use Disorders,” will address challenges to treating this patient population and highlight how advances in epidemiological and neurobehavioral research are informing our understanding of these co-occurring conditions. Speakers will review patterns in the co-occurrence of SUD and psychiatric conditions, shared risk factors and neurocognitive signatures, and gaps in mechanistic research relevant to understanding these comorbidities.
Another NIDA session is titled “Are Your Patients With Opioid Use Disorder (OUD) Worried, Losing Sleep, or Dealing With Trauma?” While medications for OUD have become the mainstay of OUD treatment, patients misusing opioids or receiving medication treatment frequently present with complexities such as sleep disturbances, anxiety, or trauma-related conditions. These conditions, if not addressed, can lead to nonadherence to treatment regimens and relapse. It is critical for OUD treatment providers to be aware of these complexities so that they can manage or treat them and give their patients the best possible opportunities for success. The presenters will describe the neural underpinnings of each of these comorbid conditions and offer guidance on mitigating their risks and managing them to improve patient outcomes.
The final session in the NIDA series, titled “The Developmental Perspective in Brain and Behavior: Analytic Tools and Findings From the Adolescent Brain Cognitive Development (ABCD) Study,” focuses on the ABCD study. This is a multisite, longitudinal study of nearly 12,000 youth starting at age 9 and 10 designed to increase understanding of how diverse experiences influence adolescent development.
The first speaker will provide a conceptual overview of analytic tools for the evaluation of neurological and behavioral development in longitudinal studies. The session will then feature four presentations by junior investigators who use different analytic approaches to answer emerging developmental questions. Collectively, these presentations will demonstrate how the design of the ABCD study and analytic methods can be leveraged to attain some of its most important study goals, including characterizing neurodevelopmental, behavioral, and health trajectories in the population.
These data will provide an unprecedented window into how the brain develops during adolescence, potentially allowing for a better understanding of what to watch out for based on an individual’s family history and lifetime experiences, such as with substance use (by themselves or family members) and video gaming, and how such factors might affect the way the adolescent brain develops.
These sessions will also examine how NIDA-supported research is both generating evidence that could improve medical practice in the treatment of patients with SUD, as well as developing innovative approaches that will allow researchers to investigate early determinants of brain development that confer risk for psychiatric disorders. ■
NOTE: The authors of this article have requested that the article be unattributed.
“Translational Perspectives on Psychiatric Comorbidities in Substance Use Disorders” and “Are Your Patients With Opioid Use Disorder (OUD) Worried, Losing Sleep, or Dealing With Trauma?” will be held Tuesday, April 28. “The Developmental Perspective in Brain and Behavior: Analytic Tools and Findings From the Adolescent Brain Cognitive Development (ABCD) Study,” will be held Sunday, April 26.

Information & Authors

Information

Published In

History

Published online: 4 February 2020
Published in print: January 18, 2019 – February 7, 2020

Keywords

  1. National Institute on Drug Abuse
  2. Opioid use disorder
  3. Substance use disorder
  4. APA’s 2020 Annual Meeting
  5. Psychiatric comorbidities
  6. Adolescent Brain Cognitive Development
  7. ABCD study

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share